Generic Name and Formulations:
Nitrofurantoin 25mg/5mL; susp.
Indications for FURADANTIN:
Take with food. 50–100mg 4 times daily. Suppressive therapy: 50–100mg once daily at bedtime may suffice.
Take with food. <1month: contraindicated. ≥1month: 5–7mg/kg per day in 4 divided doses. Suppressive therapy: 1mg/kg per day in 1–2 divided doses may suffice.
Renal impairment (CrCl <60mL/min or significantly elevated serum creatinine), anuria, oliguria. Neonates. Labor & delivery. Pregnancy at term. History of cholestatic jaundice or hepatic dysfunction.
Not for treating pyelonephritis or perinephric abscesses. Discontinue if pulmonary or hepatic disorders, hemolysis, or peripheral neuropathy occurs. Renal insufficiency. G6PD or Vit. B deficiency. Anemia. Diabetes. Electrolyte imbalance. Debilitated. Monitor renal and pulmonary function in long-term use. Pregnancy (Cat.B). Nursing mothers: not recommended.
Avoid magnesium trisilicate. Antagonized by, and increased toxicity with uricosurics (eg, probenecid). May cause false (+) glucose test with Benedict's or Fehling's solution.
Nausea, emesis, anorexia, dizziness, headache, pulmonary or hematological disorders (esp. in long-term use), peripheral neuropathy, allergic reactions, C. difficile-associated diarrhea; rare: hepatic dysfunction, exfoliative dermatitis, Stevens-Johnson syndrome, optic neuritis, methemoglobinemia.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|